SRR12202473
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.320
- KRAS_SIGNALING_DN+0.280
- MYOGENESIS+0.280
- ANGIOGENESIS+0.260
- ALLOGRAFT_REJECTION+0.250
- APICAL_SURFACE+0.240
- APICAL_JUNCTION+0.230
- IL6_JAK_STAT3_SIGNALING+0.190
- INFLAMMATORY_RESPONSE+0.170
- NOTCH_SIGNALING+0.160
Top 10 suppressed
- PROTEIN_SECRETION-0.560
- OXIDATIVE_PHOSPHORYLATION-0.480
- MYC_TARGETS_V1-0.460
- MTORC1_SIGNALING-0.430
- TGF_BETA_SIGNALING-0.430
- CHOLESTEROL_HOMEOSTASIS-0.380
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.380
- P53_PATHWAY-0.340
- UNFOLDED_PROTEIN_RESPONSE-0.340
- ANDROGEN_RESPONSE-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1337431 | GTEX | — | 0.906 |
| 2 | TCGA-91-A4BC-01A-11R-A24H-07 | — | cohortA3 | 0.900 |
| 3 | SRR1421093 | GTEX | — | 0.899 |
| 4 | MNG690 | — | — | 0.893 |
| 5 | BS_MQCKXD60 | Glial-neuronal tumor NOS | — | 0.893 |
| 6 | SRR1475803 | GTEX | — | 0.891 |
| 7 | SRR1394713 | GTEX | — | 0.890 |
| 8 | SRR1322419 | GTEX | — | 0.889 |
| 9 | SRR1486475 | GTEX | — | 0.889 |
| 10 | SRR1455305 | GTEX | — | 0.888 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.320 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.280 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.280 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.260 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.250 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.240 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.230 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.190 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.170 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.160 | Inavolisib | — uncovered |
| COAGULATION | 0.150 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.150 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.140 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.130 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.120 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.070 | Inavolisib | — uncovered |
| COMPLEMENT | 0.060 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.050 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.040 | Inavolisib | — uncovered |